NCT05400070View on ClinicalTrials.gov

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2026

Conditions
SintilimabLung CancerAnlotinibChemotherapy
Interventions
DRUG

Neoadjuvant therapy 1

Dosing regimen Sintilimab (200mg fixed dose) iv, d1, q3w + anlotinib 10mg, po, qd1-14, q3w, was evaluated after 3 cycles of chemotherapy and stopped for 3 weeks (21 days) after surgery for 4-6 weeks (21-42 days) after the last dose.

Trial Locations (1)

710038

Tangdu Hospital, the Air Force Military University, Xi'an

All Listed Sponsors
lead

Tang-Du Hospital

OTHER